Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice

American Journal of Physiology - Endocrinology and Metabolism

Volumn 302, Issue 1, 2012, Pages

  Tajima, Soichiro ^a,b   Ikeda, Yasumasa ^a   Sawada, Kaori ^a,c   Yamano, Noriko ^a   Horinouchi, Yuya ^a,b   Kihira, Yoshitaka ^a   Ishizawa, Keisuke ^a   Izawa Ishizawa, Yuki ^a   Kawazoe, Kazuyoshi ^b   Tomita, Shuhei ^a   Minakuchi, Kazuo ^b   Tsuchiya, Koichiro ^a   Tamaki, Toshiaki ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Adipose tissue; Iron; Obesity; Oxidative stress; Type 2 diabetes

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; DEFEROXAMINE; FERRITIN; IRON; PROTEIN P22; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SIZE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; FERRITIN BLOOD LEVEL; INFLAMMATION; MACROPHAGE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; TREATMENT DURATION;

ADIPOSE TISSUE, WHITE; ADIPOSITY; ANIMALS; CELL SIZE; CHELATION THERAPY; CYTOCHROME B GROUP; CYTOKINES; DEFEROXAMINE; DIABETES MELLITUS, TYPE 2; FERRITINS; GENE EXPRESSION REGULATION; IRON; IRON CHELATING AGENTS; MACROPHAGES; MALE; MICE; MICE, OBESE; NADPH OXIDASE; OBESITY; OXIDATIVE STRESS; PROTEIN SUBUNITS; RNA, MESSENGER;

EID: 83455242995     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00033.2011     Document Type: Article

References (44)

1. Andrews NC. Disorders of iron metabolism. N Engl J Med 341: 1986-1995, 1999.
2. Azumi H, Inoue N, Takeshita S, Rikitake Y, Kawashima S, Hayashi Y, Itoh H, Yokoyama M. Expression of NADH/NADPH oxidase p22phox in human coronary arteries. Circulation 100: 1494-1498, 1999.
3. Cairo G, Recalcati S, Pietrangelo A, Minotti G. The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage. Free Radic Biol Med 32: 1237-1243, 2002.
4. Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood 106: 3710-3717, 2005.
5. Cooksey RC, Jones D, Gabrielsen S, Huang J, Simcox JA, Luo B, Soesanto Y, Rienhoff H, Abel ED, McClain DA. Dietary iron restriction or iron chelation protects from diabetes and loss of beta-cell function in the obese (ob/ob lep-/-) mouse. Am J Physiol Endocrinol Metab 298: E1236-E1243, 2010.
6. Cuajungco MP, Faget KY, Huang X, Tanzi RE, Bush AI. Metal chelation as a potential therapy for Alzheimer's disease. Ann NY Acad Sci 920: 292-304, 2000.
7. Cutler P. Deferoxamine therapy in high-ferritin diabetes. Diabetes 38: 1207-1210, 1989.
8. Dongiovanni P, Valenti L, Ludovica Fracanzani A, Gatti S, Cairo G, Fargion S. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol 172: 738-747, 2008.
9. Ejiri J, Inoue N, Tsukube T, Munezane T, Hino Y, Kobayashi S, Hirata K, Kawashima S, Imajoh-Ohmi S, Hayashi Y, Yokozaki H, Okita Y, Yokoyama M. Oxidative stress in the pathogenesis of thoracic aortic aneurysm: protective role of statin and angiotensin II type 1 receptor blocker. Cardiovasc Res 59: 988-996, 2003.
10. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez- Aguado I, Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 51: 1000-1004, 2002.
11. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U. S adults Diabetes Care 22: 1978-1983, 1999.
12. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114: 1752-1761, 2004.
13. Galaris D, Skiada V, Barbouti A. Redox signaling and cancer: the role of "labile" iron. Cancer Lett 266: 21-29, 2008.
14. Gillum RF. Association of serum ferritin and indices of body fat distribution and obesity in Mexican American men-the Third National Health and Nutrition Examination Survey. Int J Obes Relat Metab Disord 25: 639-645, 2001.
15. Green A, Basile R, Rumberger JM. Transferrin and iron induce insulin resistance of glucose transport in adipocytes. Metabolism 55: 1042-1045, 2006.
16. Hagiwara S, Gohda T, Tanimoto M, Ito T, Murakoshi M, Ohara I, Yamazaki T, Matsumoto M, Horikoshi S, Funabiki K, Tomino Y. Effects of pyridoxamine (K-163) on glucose intolerance and obesity in high-fat diet C57BL/6J mice. Metabolism 58: 934-945, 2009.
17. Hayashi H, Takikawa T, Nishimura N, Yano M. Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J Hepatol 22: 268-271, 1995.
18. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 89: 986-988, 1994.
19. Ikeda Y, Aihara K, Akaike M, Sato T, Ishikawa K, Ise T, Yagi S, Iwase T, Ueda Y, Yoshida S, Azuma H, Walsh K, Tamaki T, Kato S, Matsumoto T. Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice. Mol Endocrinol 24: 1338-1348, 2010.
20. Iwasaki T, Nakajima A, Yoneda M, Yamada Y, Mukasa K, Fujita K, Fujisawa N, Wada K, Terauchi Y. Serum ferritin is associated with visceral fat area and subcutaneous fat area. Diabetes Care 28: 2486-2491, 2005.
21. Kakhlon O, Cabantchik ZI. The labile iron pool: characterization, measurement, and participation in cellular processes(1). Free Radic Biol Med 33: 1037-1046, 2002.
22. Keaney JF Jr, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, Massaro JM, Sutherland P, Vita JA, Benjamin EJ. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 23: 434-439, 2003.
23. Korac A, Verec M, Davidovic V. Insulin-induced iron loading in the rat brown adipose tissue: histochemical and electron-microscopic study. Eur J Histochem 47: 241-244, 2003.
24. Krieger-Brauer HI, Kather H. Human fat cells possess a plasma membrane- bound H2O2-generating system that is activated by insulin via a mechanism bypassing the receptor kinase. J Clin Invest 89: 1006-1013, 1992.
25. Kruszewski M. Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res 531: 81-92, 2003.
26. Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 23: 201-229, 2002.
27. Li L, Frei B. Iron chelation inhibits NF-kappaB-mediated adhesion molecule expression by inhibiting p22(phox) protein expression and NADPH oxidase activity. Arterioscler Thromb Vasc Biol 26: 2638-2643, 2006.
28. Li L, Frei B. Prolonged exposure to LPS increases iron, heme, and p22phox levels and NADPH oxidase activity in human aortic endothelial cells: inhibition by desferrioxamine. Arterioscler Thromb Vasc Biol 29: 732-738, 2009.
29. Meshkinpour H, Vaziri ND, Zhou XJ, Erickson R, Liao SY, Oveisi F, Bemanian S, Hollander D. Effects of experimental hemosiderosis on intestinal morphology, permeability, and tissue iron content. Dig Dis Sci 41: 984-988, 1996.
30. Mihara M, Aihara K, Ikeda Y, Yoshida S, Kinouchi M, Kurahashi K, Fujinaka Y, Akaike M, Matsumoto T. Inhibition of thrombin action ameliorates insulin resistance in type 2 diabetic db/db mice. Endocrinology 151: 513-519, 2010.
31. Minamiyama Y, Takemura S, Kodai S, Shinkawa H, Tsukioka T, Ichikawa H, Naito Y, Yoshikawa T, Okada S. Iron restriction improves type 2 diabetes mellitus in Otsuka Long-Evans Tokushima fatty rats. Am J Physiol Endocrinol Metab 298: E1140-E1149, 2010.
32. Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG, Keaney JF Jr, Meigs JB, Lipinska I, Kathiresan S, Murabito JM, O'Donnell CJ, Benjamin EJ, Fox CS. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 116: 1234-1241, 2007.
33. Quinn MT, Gauss KA. Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases. J Leukoc Biol 76: 760-781, 2004.
34. Rains JL, Jain SK. Oxidative stress, insulin signaling, diabetes. Free Radic Biol Med 50: 567-575, 2011.
35. Rajpathak SN, Wylie-Rosett J, Gunter MJ, Negassa A, Kabat GC, Rohan TE, Crandall J. Biomarkers of body iron stores and risk of developing type 2 diabetes. Diabetes Obes Metab 11: 472-479, 2009.
36. Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ, Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCOMCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 17: 189-212, 2001.
37. Shoham S, Youdim MB. Iron involvement in neural damage and microgliosis in models of neurodegenerative diseases. Cell Mol Biol (Noisy-legrand) 46: 743-760, 2000.
38. Tajima S, Tsuchiya K, Horinouchi Y, Ishizawa K, Ikeda Y, Kihira Y, Shono M, Kawazoe K, Tomita S, Tamaki T. Effect of angiotensin II on iron-transporting protein expression and subsequent intracellular labile iron concentration in human glomerular endothelial cells. Hypertens Res 33: 713-721, 2010.
39. Thethi TK, Parsha K, Rajapurkar M, Mukhopadhyay B, Shah S, Yau CL, Japa S, Fonseca V. Urinary catalytic iron in obesity. Clin Chem 57: 272-278, 2011.
40. Tsukamoto H, Lin M, Ohata M, Giulivi C, French SW, Brittenham G. Iron primes hepatic macrophages for NF-kappaB activation in alcoholic liver injury. Am J Physiol Gastrointest Liver Physiol 277: G1240-G1250, 1999.
41. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112: 1796-1808, 2003.
42. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112: 1821-1830, 2003.
43. Yu L, Zhen L, Dinauer MC. Biosynthesis of the phagocyte NADPH oxidase cytochrome b558. Role of heme incorporation and heterodimer formation in maturation and stability of gp91phox and p22phox subunits. J Biol Chem 272: 27288-27294, 1997.
44. Yuan X, Cong Y, Hao J, Shan Y, Zhao Z, Wang S, Chen J. Regulation of LIP level and ROS formation through interaction of H-ferritin with G-CSF receptor. J Mol Biol 339: 131-144, 2004